Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800808 | 0.79 | TRPA1 (0.40) | CYP1A2CYP2A6TRPA1ATMCA1 | |
| SCHEMBL4800802 | 0.79 | TRPA1 (0.40) | TRPA1ATMCA1CA2ALDH1A1 | |
| SCHEMBL8016156 | 0.77 | — | — | |
| SCHEMBL6391235 | 0.76 | — | — | |
| SCHEMBL8064535 | 0.70 | CYP1A2 (0.44) | CYP1A2CYP2A6TRPA1ATMCA1 | |
| SCHEMBL718918 | 0.68 | CYP1A2 (0.36) | CYP1A2CYP2A6ATMALDH1A1TSHR | |
| SCHEMBL10434554 | 0.66 | CYP1A2 (0.58) | CYP1A2CYP2A6TRPA1ATMCA1 | |
| SCHEMBL6048372 | 0.65 | ACHE (0.39) | CYP1A2CA1CA2CA7CA9 | |
| SCHEMBL18317668 | 0.64 | HPGD (0.47) | CYP1A2CYP2A6ATMALDH1A1TSHR | |
| SCHEMBL668494 | 0.64 | CYP1A2 (0.42) | CYP1A2CYP2A6TRPA1ATMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652063-B2 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7169807-B2 | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists | ALLERGAN, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070010495-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20050277751-A1 | Resin and a coating solution for forming insulating film, and a method for forming an insulating film | SUMITOMO CHEMICAL COMPANY, LIMITED | 2005-12-15 | — | — | US | disclosed |
| WO-2005100339-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | ALLERGAN, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228185-A1 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | ALLERGAN, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20040127715-A1 | Adamantane compounds and insulating film forming coating solutions | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-07-01 | — | — | US | disclosed |
| US-20030143332-A1 | Coating solution for forming insulating film | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228185-A1 | For therapy of asthma, dysmenorrhea, osteoporosis, bone disorders, constipation, renal disorders, sexual dysfunction, baldness, acute hepatitis, bronchitis, burn, chronic obstructive respiratory diseases, Crohn's disease, digestive ulcer, hemophagous syndrome, hepatopathy, hypercytokinemia at dialysis | CRHR2, HRH4, CNR2 | CYP1A2 255/4885CYP2A6 237/4885TRPA1 1581/4885 |
| US-20070010495-A1 | 10-HYDROXY-11-DIHYDROPROSTAGLANDIN ANALOGS AS SELECTIVE EP4 AGONISTS | PTGER4, PTGER2, PTGER1 | CYP1A2 296/4885CYP2A6 208/4885TRPA1 930/4885 |
| US-20030143332-A1 | Coating solution for forming insulating film | TET1, TAS1R1, ITGA1 | CYP1A2 2233/4885CYP2A6 4215/4885TRPA1 1676/4885 |
| US-20040127715-A1 | Adamantane compounds and insulating film forming coating solutions | CHRNA1, ANO1, CHRNA2 | CYP1A2 298/4885CYP2A6 2168/4885TRPA1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.